Discontinued — last reported Q4 '17

Non-Current Assets

Indefinite-Lived Research and Development Assets

Corvex Indefinite-Lived Research and Development Assets decreased by 46.9% to $1.43M in Q4 2025 compared to the prior quarter. Over 3 years (FY 2022 to FY 2025), Indefinite-Lived Research and Development Assets shows relatively stable performance with a 0.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2017

How to read this metric

An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.

Detailed definition

This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...

Peer comparison

Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.

Metric ID: indefinite_lived_rd_assets

Historical Data

4 periods
 Q4 '22Q4 '23Q4 '24Q4 '25
Value$1.43M$2.70M$2.70M$1.43M
QoQ Change+88.5%-0.1%-46.9%
YoY Change+88.5%-0.1%-46.9%
Range$1.43M$2.70M
Avg YoY Growth+13.8%
Median YoY Growth-0.1%
Current Streak2 quarters decline

Frequently Asked Questions

What is Corvex 's indefinite-lived research and development assets?
Corvex (MOVE) reported indefinite-lived research and development assets of $1.43M in Q4 2025.
What is the long-term trend for Corvex 's indefinite-lived research and development assets?
Over 3 years (2022 to 2025), Corvex 's indefinite-lived research and development assets has grown at a 0.0% compound annual growth rate (CAGR), from $1.43M to $1.43M.
What does indefinite-lived research and development assets mean?
The value of ongoing research projects acquired from other companies that are not yet ready for sale.